Lung Cancer Trials Ask AI to find trials
TerminatedPhase 1NCT04272034
Official study title

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Study summary

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedINCB099318

The study team can explain what participation involves.

Who it may be forMesothelioma · PD-L1 · Early-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 16, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?24 U.S. locations

Locations may change over time.

Who runs it?Incyte Corporation

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Incyte Corporation
Interventions being studied
Drug: INCB099318
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Mesothelioma→
Disease setting
Early-stage or resectable→Metastatic or stage IV→
Biomarkers
PD-L1→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Must have disease progression after treatment with available therapies that are known to confer clinical benefit or must be intolerant to or ineligible for standard treatment.
  • Histologically confirmed advanced solid tumors (protocol-defined select solid tumors) with measurable lesions per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) that are considered nonamenable to surgery or other curative treatments or procedures.
  • ECOG performance status score of 0 or 1.
  • Life expectancy \> 12 weeks.
  • Willingness to avoid pregnancy or fathering children.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Hackensack University Medical CenterHackensack, New Jersey
  • Prisma Health Cancer Institute FarisGreenville, South Carolina
  • Vanderbilt-Ingram Cancer CenterNashville, Tennessee
  • Universitair Ziekenhuis BrusselBrussels
  • Institut Jules BordetBrussels
  • Universitair Ziekenhuis Antwerpen (Uza)Edegem
  • Ghent University HospitalGhent
  • Universitaire Ziekenhuis Leuven - GasthuisbergLeuven
  • Rigshospitalet Uni of Hospital of CopenhagenCopenhagen
  • Helsinki University Central HospitalHelsinki
  • Docrates Cancer CenterHelsinki
  • Tampere University HospitalTampere

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 16, 2025. Always confirm current availability with the study team.

View original record ↗